AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...
Rhythm specializes in treatments for metabolic conditions and severe obesity.
By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire ...
Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, the ...
Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...
Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not ...
AstraZeneca PLC (LSE:AZN, NYSE:AZN), the Anglo-Swedish drugmaker, saw three brokers raise their price targets after its third ...
AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...
AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the pharmaceutical industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results